American Journal of Psychiatry (AM J PSYCHIAT )
The American Journal of Psychiatry is the most widely read psychiatric journal in the world. Published monthly, it is indispensable for all psychiatrists and other mental health professionals who need to keep up-to-date with all aspects of psychiatry. Peer-reviewed articles focus on developments in biological psychiatry as well as on treatment innovations and forensic, ethical, economic, and social topics. Letters to the editor and book reviews also appear in each issue; official American Psychiatric Association reports appear from time to time. Of special interest are the overview and other special lead articles, which treat major psychiatric syndromes and issues in depth.
- Impact factor14.72Show impact factor historyHide impact factor history
- 5-year impact14.40
- Cited half-life0.00
- Immediacy index2.57
- Article influence5.54
- WebsiteAmerican Journal of Psychiatry website
- Other titlesThe American journal of psychiatry
- Material typePeriodical, Internet resource
- Document typeJournal / Magazine / Newspaper, Internet Resource
- Author can archive a pre-print version
- Author cannot archive a post-print version
- 12 months embargo for authors version
- Authors final version of accepted manuscript
- Any repository
- NIH and Wellcome Trust authors may meet their funders requirements
- Publisher's version/PDF cannot be used
- Publisher copyright statement and source including DOI must be acknowledged
- Must link to publisher version on publisher's website at journals.psychiatryonline.org with the phrase: "The official published article is available online at ."
- If author selects publisher's "immediate public access" program (fee based), publisher will deposit in PubMed Central on behalf of author the official published version for release immediately on publication in journal
- Classification yellow
Publications in this journal
- American Journal of Psychiatry 12/2012; 169(12):1321.
Article: Genetic Variation in KCNH2 Associated with Expression in Brain of a unique hERG Isoform Modulates Treatment Response in Patients with Schizophrenia José A. Apud M.D., PhD*, Fengyu Zhang, Ph.D.*, Heather Decot, B.S., Kristin L. Bigos, Ph.D.#, Daniel R. Weinberger M.D.#. From the Clinical Brain Disorders Branch, Genes, Cognition and Psychosis Program, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.[show abstract] [hide abstract]
ABSTRACT: O b je c t iv e : Antidopaminergic drugs bind to hERG1 potassium channels encoded by the gene KCNH2, which accounts for the side effect of QT interval prolongation. KCNH2 has also been associated with schizophrenia risk, and risk alleles predict increased expression of a brain-selective isoform, KCNH2 3.1, that has unique physiological properties. The authors assessed whether genetic variation associated with KCNH2 3.1 expression influences the therapeutic effects of antipsychotic drugs. M e th o d : The authors performed a pharmacogenetic analysis of antipsychotic treatment response in patients with schizophrenia using data from two independent studies: a National Institute of Mental Health (NIMH) double-blind, placebo-controlled inpatient crossover trial (N=54) and the multicenter outpatient Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) study (N=364). The KCNH2 genotype that was previously associated with increased expression of KCNH2 3.1 in the brain was treated as a predictor variable. Treatment-associated changes in symptoms were evaluated in both groups with the Positive and Negative Syndrome Scale. The authors also analyzed time to discontinuation in the olanzapine arm of the CATIE study. R e su lt s : In the NIMH study, individuals who were homozygous for the KCNH2 3.1 increased expression-associated T allele of rs1036145 showed significant improvement in positive symptoms, general psychopathology, and thought disturbance, while patients with other genotypes showed little change. In the CATIE study, analogous significant genotypic effects were observed. Moreover, individuals who were homozygous for the T allele at rs1036145 were one-fifth as likely to discontinue olanzapine. C o n c lu s io n s : These consistent findings in two markedly different treatment studies support the hypothesis that hERG1-mediated effects of antipsychotics may not be limited to their potential cardiovascular side effects but may also involve therapeutic actions related to the brainspecific 3.1 isoform of KCNH2.American Journal of Psychiatry 01/2012; 169:1-10.
- American Journal of Psychiatry 01/2011; 168(6):649.
Article: Green, M. F., Schooler, N. R, Kern, R. S., Frese, F. J., Granberry, W., Harvey, P. D., Karson, C. N., Peters, N., Stewart, M., Seidman, L. J., Sonnenberg, J., Stone, W. S., Walling, D., Stover, E., & Marder, S. R. (2011). Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. American Journal of Psychiatry, 168(4), 400-407.American Journal of Psychiatry 01/2011; 168(4):400-407.
- American Journal of Psychiatry 05/2008; 165(4):420-3.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
ISSN: 2045-7758, Impact factor: 1.18
American Psychological Association,...
ISSN: 1939-2117, Impact factor: 4.85
ISSN: 1878-1888, Impact factor: 2.85
Food and chemical toxicology: an international journal published for the British Industrial Biologic...
ISSN: 1873-6351, Impact factor: 2.99
United States. Alcohol, Drug Abuse,...
ISSN: 1745-1701, Impact factor: 8.8
World Psychiatric Association
ISSN: 1723-8617, Impact factor: 8.97